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Abstract: The rate of hypertension increases after menopause. Whether estrogen and proges-
terone deficiency associated with menopause play a role in determining a worst blood pressure 
(BP) control is still controversial. Also, studies dealing with the administration of estrogens 
or hormone therapy (HT) have reported conflicting evidence. In general it seems that, despite 
some negative data on subgroups of later postmenopausal women obtained with oral estrogens, 
in particular conjugated equine estrogens (CEE), most of the data indicate neutral or beneficial 
effects of estrogen or HT administration on BP control of both normotensive and hypertensive 
women. Data obtained with ambulatory BP monitoring and with transdermal estrogens are more 
convincing and concordant in defining positive effect on BP control of both normotensive and 
hypertensive postmenopausal women. Overall progestin adjunct does not hamper the effect of 
estrogens. Among progestins, drospirenone, a spironolactone-derived molecule, appears to be 
the molecule with the best antihypertensive properties.
Keywords: hormone replacement therapy, estrogen, progestin, blood pressure, menopause, 
hypertension
Introduction
Hypertension is a continuous, non-occasional state of elevated blood pressure (BP). BP 
increases with age. As a consequence of longer life expectancy and modern lifestyle, 
the prevalence of hypertension is expected to increase.1 While diastolic BP starts to 
increase earlier, systolic BP starts to increase after 50 years of age. The increase of 
systolic BP is a higher health risk. A higher incidence of cardiovascular and cerebro-
vascular diseases is observed respectively 10 and 20 years after BP increase.2 A 2012 
World Health Organization report shows that the rise of BP causes 51% of deaths from 
stroke, and 45% of deaths from coronary artery diseases.3
There are sex differences in the development of hypertension. The National Health 
and Nutrition Examination Survey (NHANES) shows that, prior to 45 years of age, 
prevalence of hypertension is higher in men than in women. From 45 to 54 years and 
from 55 to 64 years of age, the percentage of hypertensive men is similar to that of 
hypertensive women. After 65 years of age, BP levels increase faster in women than 
in men.4
It has been suggested that sex steroids protect fertile women from hyperten-
sion, and that gonadal steroid withdrawal may play a role in the modifications of 
BP control.5 In fact, the role played by steroid withdrawal at menopause is still 
controversial.
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Menopause and BP
Cross-sectional studies show that hypertension is two times 
more prevalent in post- than in pre-menopausal women, 
regardless of age and body mass index (BMI),6 and that 
this prevalence is reduced by the use of hormone therapy 
(HT).7 In a cross-sectional Italian investigation performed on 
22,250 women around the menopause, the postmenopausal 
status doubled the risk of developing hypertension.8 Similar 
results were observed in a study on hypertension prevalence 
in menopause in the Italian population, a cross-sectional 
investigation on 18,326 women from 46 to 59 years of 
age.9 Regardless of confoundings in the study, systolic and 
diastolic BP were slightly but significantly higher (+3.4 and 
+3.1 mmHg, respectively) in post- than in pre- and peri-
menopausal women. A recent article evaluating 908 female 
residents aged 45–54 years in a Prague district linked the 
postmenopausal BP rise to the increase of BMI,10 which is 
commonly observed in the menopausal transition.11–13
In spite of these evidences, other studies could not find 
a direct correlation between the menopause event and the 
development of hypertension. In a 16-year study performed 
on 525 Italian pre- and post-menopausal women, systolic BP 
was found to be related to age, but not to hormonal status.14 
Similarly, no correlation between menopausal status and 
hypertension emerged in a cross-sectional study on more 
than 22,000 Japanese post-menopausal women, once the data 
were adjusted for age and time since menopause.15 Similarly, 
a 16-year longitudinal study on more than 9,000 women 
aged 18–70 years showed that the worst BP profile observed 
in postmenopausal women was not the consequence of the 
menopausal status.16
Sex steroid effects on blood vessels
Experimental data indicate that gonadal steroids may regulate 
blood vessel functions. Estrogens influence the activity of 
endothelial cells, via genomic and non-genomic signaling. 
By binding to ERα, estrogens increase the production of 
vasodilating agents such as nitric-oxide, prostacyclin and 
prostaglandin E2 and reduce oxidative stress and proin-
flammatory cytokines.17–20 The binding of estrogens to ERβ 
modulates the expression of ERα and antagonizes some of 
the beneficial effects of estrogens.21 Interestingly, ERβ are 
overexpressed in women with a higher incidence of coronary 
artery disease.22 In addition to effects mediated by endothe-
lial cells, estrogens may vasodilate vessels via an influence 
on calcium-dependent potassium channels, and a block of 
calcium channels.23,24 Progesterone itself, when binding to 
its receptor, may exert vasodilating effects,25 depending on 
the vessel and on the levels of the hormone,26,27 sometimes 
antagonizing the effect of estrogens.27
Studies in vivo have shown that estrogens administered 
acutely and in high doses exert vasodilating effects,28–34 
which are also observed,35–38 although inconsistently,39–40 with 
the prolonged administration of lower estrogen doses. This 
endothelium-mediated dilating effect of estrogens disappears 
in women with endothelium alterations41 and appears to 
decrease with time since menopause, being lost several years 
after the menopause.41,42 In this situation, the administration 
of estrogens appears to be deleterious by favoring a shift 
towards the production of proinflammatory cytokines.42
The concomitant administration of progestins may 
antagonize the vasodilating effect of estrogens. Conflicting 
data have been reported for medroxyprogesterone acetate 
(MPA)43,44 and norethisterone acetate (NETA),45,46 and more 
neutral effect for desogestrel (DSG)47 and physiological doses 
of progesterone.48
Beside the direct effect on endothelial cells, complex 
modulation of the renin–angiotesin–aldosterone axis,49–53 as 
well as of the adrenergic stimulus41,54,55 should be taken into 
consideration when evaluating the possible influence of sex 
steroids or of their administration on the control of BP.
HT and BP
On the basis of actual knowledge it can be hypothesized that 
in postmenopausal women the administration of HT influ-
ences BP control. This effect may vary depending on the type 
of estrogen used, its dosage, its route of administration, and 
the progestin molecule eventually associated. Recent versus 
late postmenopausal women may also differ in their response. 
Indeed, there are a relevant number of studies dealing with 
the interaction between HT and BP regulation, and the results 
are often conflicting.56
The present review summarizes actual knowledge of 
the effect of postmenopausal HT in modifying BP control. 
The effect of HT is presented separately for normotensive 
and hypertensive women. For each condition, data obtained 
with estrogen alone, estrogen plus progestin and the effect 
of different progestins are summarized. Data obtained with 
office and ambulatory blood pressure measurement are pre-
sented in sequence, grouped according to their concordance. 
Concordant data are presented in chronological order with 
cross-sectional studies preceding randomized clinical trials. 
Studies were retrieved by PubMed search and limited to the 
years 1980 to 2013. The research was implemented using 
references cited in selected articles. Search terms were 
menopause, blood pressure, hypertension, hormone therapy, 
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estrogen, and progestin. Only articles in the English language 
were retrieved.
HT in normotensive women
HT with estrogens alone  
in normotensive women
In the Rancho Bernardo study, a cross-sectional investiga-
tion of 1,044 postmenopausal women, the use of conjugated 
equine estrogens (CEE) for ten years seemed to induce a 
better BP control than in non-users.57
These data were not confirmed by some clinical tri-
als (Table 1). In the Women’s Health Initiative (WHI), 
a placebo-controlled trial performed on more than 
10,000 hysterectomized women 50–79 years of age with a 
mean age of 63.6 years at enrollment, 0.625 mg/d of CEE 
induced a small but significant increase of systolic BP.58
Similar data were obtained in a 9-month prospective 
comparative study on 160 normotensive postmenopausal 
women, aged 52 years, where administration of CEE was 
associated with a marked elevation of BP.59 During CEE 
administration, systolic BP increased more than 15 mmHg 
in about 20% of women treated, and diastolic BP increased 
more than 15 mmHg in 10% of the women.59 Negative 
effects of CEE on BP were further published by the same 
authors in another study.60 Interestingly, the administration 
of only estrone sulfate decreased BP. Because 50% of CEE 
is made by estrone sulfate, the negative effect of CEE on 
BP may be due to equiline derivatives (30%–40%) or other 
components that do not naturally occur in the human. In the 
Estrogen in the Prevention of Atherosclerosis Trial (EPAT), 
a placebo-controlled trial on 222 normotensive or hyperten-
sive postmenopausal women, micronized estradiol (1 mg) 
instead of CEE was orally administered. Different effects 
were observed between younger and older women. In the 
former, systolic BP slightly increased; in the latter, diastolic 
BP slightly decreased.61
Several studies have placed their primary objective on the 
effect that estrogens exert on the control of BP throughout the 
24-hour period (Table 1). These studies, although smaller in 
sample size, are stronger in terms of measurement, and more 
reliable than studies in which BP evaluation was performed 
by single office measurement and as a secondary objective 
of the study. In these studies, oral estrogens either increased 
(E2)62 or did not modify (CEE) 24-hour BP values.63,64 Trans-
dermal estradiol instead was reported to decrease ambulatory 
BP in almost all studies reviewed (Table 1).
In 90 normotensive women 30 to 59 years of age in sur-
gical menopause, randomized to a 6-month treatment with 
oral (combination of E2, estrone [E1], and estriol [E3]) or 
transdermal estrogens, nighttime systolic and both nighttime 
and daytime diastolic BPs decreased by about 4 mmHg in the 
transdermal but not in the oral estrogen group.63 In a placebo-
controlled study performed in 18 normotensive healthy post-
menopausal women, transdermal E2 (50 µg/day per 8 weeks) 
Table 1 Clinical trials investigating the effect of estrogens on blood pressure of normotensive postmenopausal women
Source of  
trial
Year of 
trial
Age of  
subjects
Number of 
subjects
Route of  
administration  
of estrogens
Estrogens  
administered
BP measurement 
mode
Effects of estrogens
WHI58 2004 63.6 ∼10,000 Oral Cee 0.625 mg Office ↑ systolic BP
Wren59 1981 52 160 Oral e1 sulphate + 
Cee 0.625 mg
24-h ↓ BP 
↑ BP
ePAT61 2008 61 222 Oral e2 1 mg Office ↑ systolic BP in younger 
↓ diastolic BP in older
Akkad63 1997 30–59 90 Transdermal 
Oral
e2 0.05 mg 
e2 + e3 + e1
24-h ↓ nocturnal systolic BP 
↓ diastolic BP 
=24-h BP
Cardoso62 2011 45–60 47 Oral e2v 1 mg 24-h ↑ systolic BP 
↑ diastolic BP
vongpatanasin64 2001 53 12 Transdermal  
Oral
e2 0.2 mg 
Cee 0.625 mg
24-h ↓ 24-h BP 
=24-h BP
Cagnacci65 1999 53.5 18 Transdermal e2 0.05 mg 24-h ↓ nocturnal systolic BP 
↓ nocturnal diastolic BP 
↓ nocturnal mean BP
Driul66 2005 51.3 46 Transdermal e2 0.05 mg 24-h ↓ diurnal diastolic BP 
↓ nocturnal diastolic BP
Abbreviations: 24-h, 24-hour; BP, blood pressure; CEE, conjugated equine estrogen; EPAT, Estrogen in the Prevention of Atherosclerosis Trial; E1, estrone; E2, estradiol; 
e2v, oral estradiol valerate; e3, estriol; WHI, Women’s Health Initiative; ↓, decrease; ↑, increase; =, no change.
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magnified the nocturnal decrement of systolic (14.3±7.2 
versus 9.8±6.7 mmHg, P=0.0033),  diastolic (11.6±5.0 ver-
sus 7.5±7.3 mmHg, P=0.028), and mean (10.8±5.6 versus 
7.2±4.5 mmHg, P=0.011) BP.65 In a randomized crossover 
placebo-controlled study on 12 normotensive women, tak-
ing transdermal E2 (200 µg/day), oral CEE (0.625 mg/d), or 
placebo for 8 weeks, a small but significant decline of ambu-
latory BP was observed only with transdermal E2.64 Finally, 
in a group of 46 women in surgical menopause (mean age of 
51 years), transdermal E2 (50 µg/day) significantly decreased 
diurnal and nocturnal diastolic BP in the subgroup of smokers 
(n=30, 65.2%).66
HT with estrogens plus progestins  
in normotensive women
Data on the effect of HT on office BP are rather conflicting; 
positive, neutral or negative effects have been reported. 
A positive effect was observed in the Coronary Risk Factors 
for Atherosclerosis in women (CORA) study. In this case 
control study, 200 consecutive pre- and post-menopausal 
women with incident coronary heart disease were matched 
with 255 controls. The study showed beneficial effects of 
HT on BP control of postmenopausal women with a previ-
ous cardiovascular disease.67 Similar data were obtained in 
the Baltimore longitudinal study on aging, an observational 
study on 226 healthy, normotensive postmenopausal women 
aged 64±10 years, who were followed for a mean period 
of 5.7 years. Seventy-seven women used either oral or trans-
dermal estrogen plus progestin, and 149 used no hormone. 
After 10 years of follow-up, postmenopausal women taking 
HT showed a smaller increase in systolic BP versus non-users 
(7.6 mmHg versus 18.7 mmHg after 10 years), which was 
more evident in older women.68
Hassager and Christiansen69 published a summary of five 
trials performed with oral and transdermal estrogen associ-
ated with NETA, CPA, or micronized progesterone in about 
270 women enrolled either earlier after or later after the 
menopause. The results of those trials indicate that any HT 
regimen decreases BP, particularly diastolic BP, of women 
earlier after the menopause. However, HT does not exert any 
effect in women later after the menopause (Table 2).69
No effect of HT on office BP was observed in two major 
trials, the Postmenopausal Estrogen/ Progestin  Interventions 
(PEPI) trial,70 and the Danish Osteoporosis  Prevention Study 
(DOPS)71 (Table 2).
The PEPI trial evaluated the effects on the cardio-
vascular systems of 875 healthy postmenopausal women 
(45 to 64 years of age) of four estro-progestinic regimens 
(CEE, 0.625 mg/d; CEE, 0.625 mg/d plus cyclic MPA 
10 mg/d for 12 d/month; CEE, 0.625 mg/d plus consecutive 
MPA, 2.5 mg/d; or CEE, 0.625 mg/d plus cyclic micronized 
progesterone [MP], 200 mg/d for 12 d/month; or placebo 
alone). No significant difference in BP was observed among 
treatments and placebo. Similarly, there was no difference 
associated with the different types and doses of progestin 
used.70 In the DOPS study, women taking for five years oral 
E2, alone or in association with NETA, did not experience a 
reduction of BP in comparison to users of placebo.71 A nega-
tive effect of HT on BP was observed in one observational 
and two major clinical trials (Table 2).72–74
In  a  recent  Aust ra l ian  s tudy perfor med on 
43,405  normotensive postmenopausal women, HT use 
was associated with significantly higher odds of having 
high BP, the risk becoming higher with longer HT use.72 An 
increase of BP induced by HT was also observed in two major 
placebo-controlled trials, such as the WHI and the Heart and 
Estrogen/Progestin Replacement Study (HERS).
The WHI investigation evaluated 16,608 women, aged 
50–79 years, taking CEE plus MPA or placebo. After 
two years of treatment with HT, there was an increase of 
1.5 mmHg of systolic but not of diastolic BP. Furthermore, 
women taking HT showed a 25% increased risk of devel-
oping hypertension.73 In the HERS study, performed on 
women with cardiovascular disease, an increase of systolic 
BP was described in women receiving CEE plus MPA versus 
placebo.74
More reassuring are the data of studies performed with 
24-hour ambulatory BP monitoring (Table 2). Oral E2 
(1 mg) combined with 5 or 10 mg dihydrogesterone (DYD) 
to 29 healthy normotensive postmenopausal women (mean 
age 52.3 years) induced a decrease of 24-hour systolic and 
diastolic BP in comparison to control women.75
Harvey et al76 monitored 24-hour BP of 24 normotensive 
postmenopausal women (median age 54 years). For each 
subject there were four randomized treatment phases, each 
lasting 4 weeks. The treatments were 0.625 mg estrone 
 sulphate, 2.5 mg estrone sulphate, 0.02 mg ethinylestradiol, 
all of them associated to 10 mg of oral MPA for 14 days, 
and matching placebo. Combinations containing either 
natural or semisynthetic estrogen reduced nighttime ambu-
latory BP.76
In a placebo-controlled, randomized crossover study, 
sixteen healthy normotensive post-menopausal women 
(age 55±3 years) were randomized to E2 plus cyclic 
NETA or placebo in two 12-week periods of treatment. Ambu-
latory  systolic and diastolic BP were reduced after 10 days of 
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E2 (−5.1 and −3.2 mmHg, respectively). During the addition 
of NETA, diastolic BP was further reduced (−3.6 mmHg), 
suggesting additive BP-lowering effects of this molecule.77 
In a 3-month randomized double-blind placebo-controlled 
crossover trial performed in 17 normotensive postmenopausal 
women, CEE (0.625 mg/day) alone or associated with continu-
ous MPA (5 mg/day) reduced 24-hour diastolic BP by 4 and 5 
mmHg, and systolic BP by 6 and 9 mmHg, respectively.78 In 
a randomized study of 73  normotensive women, a significant 
decrease of daytime systolic BP was observed after 2 months 
of treatment with 2 mg of oral (3.8±0.2 mmHg) or 50 µg of 
transdermal E2 (4.0±0.3 mmHg), both sequentially associated 
with NETA. Mean daytime BP also decreased, both in the oral 
(−1.8±0.8 mmHg) and transdermal (−3.5±0.7 mmHg) groups. 
Nighttime BP remained unaffected by either treatment.79 In 
another study, 8 weeks of treatment with E2, oral or trans-
dermal plus NETA, significantly reduced 24-hour systolic 
BP of about 4–5 mmHg.80 Sixty patients (aged 59 years) 
were randomized to receive 0.625 mg/day CEE, or 50 µg/day 
transdermal E2 or placebo for 18 days, then treatments were 
combined with 5 mg MPA for an additional 10 days. After one 
year of therapy, night-time systolic BP decreased significantly 
in the CEE group, and both systolic and diastolic BP decreased 
significantly in the transdermal group.81 In 28 postmenopausal 
women 45 to 55 years of age, oral estradiol valerate (E2V) 
(2 mg) or transdermal estradiol (0.05 mg) decreased 24-hour 
systolic BP.82 Similarly, in a placebo-controlled study the 
association of transdermal E2 (0.2 mg/day) plus intravaginal 
progesterone (300 mg/day) significantly decreased nighttime 
systolic, diastolic, and mean BP in 15 healthy postmenopausal 
women. Daytime BP followed the same trend, but was signifi-
cantly lower only for mean BP. The addition of progesterone 
resulted in no further fall.83
HT with progestins  
in normotensive women
There are few studies reporting the effects of progestins 
on the vascular system. Progestins are a multitude of com-
pounds, and their effect may vary depending on different 
pharmacokinetic properties, type of molecule, and route of 
administration, some negative effects being evident with 
the oral but not the transdermal route of administration.84 In 
addition, the major negative effects of progestins are related 
to vascular damages and injuries that are already estabilished. 
For this reason, conflicting evidence may be present in the 
literature.85
An antihypertensive effect of oral progesterone was 
described in four hypertensive women and six hypertensive 
men.86 Several studies have investigated whether the admin-
istration of different progestins can influence BP regulation 
(Table 2).
HT with chlormadinone acetate  
and NeTA in normotensive women
A study on 416 women tested the effect of chlormadinone 
acetate (CMA) (2 mg/day), a C21 gestagen with antiandro-
genic properties, and NETA (1 mg/day), a C19 gestagen 
with androgenic properties, given in sequential combination 
(12 days/cycle) with transdermal E2 (0.05 mg/day). No 
significant effects were observed over the 4-month period 
of treatment.87
In a prospective randomized comparison, different doses 
of CMA (0.5, 1.0, 2.0, and 3.0 mg per day) in association with 
transdermal or oral E2 were tested on 159 postmenopausal 
women. CMA in any dose did not modify BP.88
HT with dienogest  
in normotensive women
Mueck et al also tested the effects of dienogest (DNG), 
another C19 gestagen with antiandrogenic properties, on 
BP. In a randomized comparison of 0.5, 1, 2, 3, and 4 mg 
of DNG continuously combined with E2 for 6 months, no 
effect of increasing DNG dose was observed on BP.89 In 
addition, DNG adjunct did not modify the effect exerted by 
E2 alone.90
HT with dihydrogesterone  
in normotensive women
In another study, 563 postmenopausal women were treated 
with micronized E2 (2 mg), sequentially combined with 
various doses of DYD. After 6 months of treatment, a slight 
but significant fall of systolic and diastolic BP was registered 
for the entire pooled group. After 1 year, however, the group 
receiving 10 mg of DYD showed a significant rise (about 
2–3 mmHg) of both systolic and diastolic BP.91 In another 
study, DYD in doses ranging between 5 and 20 mg per day, 
combined with 1 or 2 mg of E2, appeared to be particularly 
neutral in terms of both metabolic and vascular effects.92
HT with MPA in normotensive women
In a double-blind crossover study, 20 normotensive post-
menopausal women (median age 53 years) were randomized 
to four MPA treatment phases of 4 weeks each. CEE 0.625 mg 
was associated with MPA 2.5 mg, MPA 5 mg, MPA 10 mg, or 
placebo, in the last 14 days of each 28-day treatment cycle. 
In comparison to placebo, during progestin administration 
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there was a dose-dependent decrease of ambulatory daytime 
diastolic and mean BP.93
HT with drospirenone  
in normotensive women
Drospirenone (DRSP) is derived from spironolactone, and 
possesses antialdosteronic properties. This molecule can 
control water retention, weight increase, and BP levels. 
Several papers deal with the capability of DRSP to reduce 
BP in hypertensive women.94–97 On the other hand, clinical 
studies performed in normotensive women did not report 
any effect of DRSP on BP. In a group of 30 women randomly 
treated with either DRSP 2 mg/E2 1 mg or with NETA 0.5 
mg/E2 1 mg, no significant difference was observed in 
24-hour, daytime, and nighttime BP values.98 In another 
Italian study, postmenopausal women were treated with 
E2 (1 mg/day) plus DRSP (2 mg/day). Both systolic and 
diastolic BP did not vary. In subjects with systolic BP 
lower than 130 mmHg at baseline, no changes in systolic 
BP values were registered, while women with baseline 
high-normal systolic BP (130–139 mmHg) experienced a 
significant BP decline.99
Hypertensive women
HT with estrogens alone  
in hypertensive women
There are few studies dealing with the effect of estogens 
alone in hypertensive postmenopausal women (Table 3). 
In a randomized placebo-controlled study, 2 mg or 4 mg 
of micronized E2 were given to 20 normotensive and 
20 hypertensive postmenopausal women.100 E2 decreased 
systolic and diastolic BP in both normotensive and 
hypertensive women. The decrease of BP was more 
clear in hypertensive than normotensive subjects. In a 
randomized double-blind placebo-controlled study per-
formed in 30 hypertensive women (mean age 55 years), 
 transdermal E2 (0.05 mg/day) significantly decreased 
24-hour systolic and diastolic BP. Furthermore, in the 
non-dipper subgroup, E2 restored the expected reduction 
of BP at night.101
Table 3 Clinical trials investigating the effect of estrogens alone or with hormone therapy on blood pressure of hypertensive postme-
nopausal women
Source of trial Year of  
trial
Number  
of subjects
Routes of  
administration
Estrogens Progestins Mode of  
measurement
Effects
Luotola100 1983 40 Oral e2 2 mg 
e2 4 mg
– Office ↓ diastolic BP 
↓ systolic BP
Mercuro101 1998 30 Transdermal e2 50 µg – 24-h ↓ diastolic BP 
↓ systolic BP
Kornhauser104 1997 55 Oral 
Oral + im
estradiol valerate 10 mg 
estradiol valerate 4 mg
– 
Prasterone  
enanthate 200 mg
Office ↑ systolic BP 
↑ diastolic BP
Jespersen105 1993 24 Oral e2 
e2 + e1
– 
NeTA
Office ↓ systolic BP 
= diastolic BP
van der Mooren91 1996 99 Oral e2 DYD Office ↑ systolic BP 
↑ diastolic BP
Harvey106 2000 14 Oral Cee 0.3, 0.625, 1.25 mg MPA 10 mg Office ↓ BP
Mueck102 2000 13,190 Oral Cee 0.3, 0.625, 1.25 mg MPA 10 mg Office ↓ systolic BP 
↓ diastolic BP
Foidart108 1991 92 Transdermal +  
Oral
e2 50 µg MPA 10 mg Office = diastolic BP 
= systolic BP
Sumino107 2003 31 Oral Cee 0.625 mg MPA 2.5 mg Office = BP
Kaya110 2006 66 Oral e2 1 mg DYD 10 mg 24-h ↓ systolic BP 
↓ diastolic BP 
↓ mean BP
Wong111 2005 34 Oral e2 Norgestrel 24-h ↓ daily mean BP
Affinito112 2001 60 Transdermal e2 50 µg MPA 10 mg 24-h ↓ diastolic BP 
↓ systolic BP
Szekacs114 2000 30 Transdermal e2 50 µg Norgestrel 24-h ↓ diastolic BP 
↓ systolic BP
Abbreviations: 24-h, 24-hour; BP, blood pressure; CEE, conjugated equine estrogen; DYD, dihydrogesterone; E1, estrone; E2, estradiol; im, intramuscular; MPA, 
medroxyprogesterone acetate; NeTA, norethisterone acetate; ↓, decrease; ↑, increase; =, no change, –, none.
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HT with estrogens plus progestins  
in hypertensive women
A revision of case-control and cross-sectional studies pub-
lished between 1960 and 2004 reported that HT, performed 
with either oral or transdermal estrogen, does not consis-
tently increase BP.102 In the Italian Climacteric Research 
Group Study (ICARUS), an observational investigation 
on 9,309 women, HT use was associated with significantly 
lower BP values in both normotensive and hypertensive 
women.103 In a randomized double-blind placebo-controlled 
trial performed in 55 postmenopausal women with mild 
to moderate hypertension, 4 mg and 10 mg of E2 valer-
ate plus 200 mg prasterone enanthate, administered for 
3 months, did not induce any change of BP (Table 3).104 
Jespersen et al investigated the effects of a 6-month treat-
ment with E2 either alone or in sequential association with 
NETA on 24  postmenopausal women (12 normotensive 
and 12 hypertensive). In normotensive women, HT did not 
significantly modify systolic or diastolic BP. However, in 
hypertensive women systolic BP fell significantly during the 
treatment with either E2 or E2 plus NETA.105
On the other hand, the administration of oral E2 
plus DYD caused an increase of 6.8 and 8.6 mmHg of 
systolic and diastolic BP, respectively, in a group of 
99 hypertensive women.91 Fourteen postmenopausal women 
with grade 1–2 hypertension were enrolled in a double blind 
crossover study. There were four randomized treatment 
phases, each lasting 4 weeks: CEE 0.3 mg, CEE 0.625 mg, 
CEE 1.25 mg and placebo. Each subject also received MPA 
(10 mg for 14 days). In hypertensive postmenopausal women, 
HT exerted a variable effect on BP that was dependent on 
CEE dose. The “lower” and “middle” doses of CEE produced 
a small reduction of BP, which tended to reverse with the 
“higher” CEE dose.106
Studies with transdermal estradiol and office BP measure-
ment do show either a neutral or BP lowering effect (Table 3). 
A study was performed on 13,910 post-menopausal women, 
some of whom (n=1,516) were taking transdermal E2 (0.025, 
0.05, and 0.01 mg daily) with or without progestin (NETA 
47.2%, MPA 23.8%, medrogestone 10.8%, CMA 2.0%, 
or DYD 1.5%). After 2 months of treatment there was no 
effect of treatments on BP of normotensive women, while a 
decrease of office systolic and diastolic BP was observed in 
hypertensive women (2–3 mmHg). In women with baseline 
diastolic BP higher than 100 mmHg, systolic BP decreased 
7 mmHg and diastolic BP decreased 9 mmHg.107 In another 
study performed on 92 hypertensive postmenpausal women, 
the 6-month administration of transdermal E2 plus 10 mg 
MPA did not cause any significant variation of office systolic 
and diastolic BP.108
Studies with 24-hour ambulatory BP monitoring report 
more consistent evidence of a BP lowering effect exerted 
by HT (Table 3). In one study performed on 31 hyperten-
sive women, CEE in doses of 0.625 mg per day did not 
modify 24-hour ambulatory BP.109 However, in two other 
studies performed with oral E2, a decrease of 24-hour BP 
was observed during treatment. In a 12-month prospective 
study, 66 postmenopausal women with mild to moderate 
hypertension were randomly assigned to receive 1 mg/day 
micronized E2 sequentially combined with MPA 10 mg/day, 
or no therapy. A significant fall in 24-hour systolic, diastolic, 
and mean BP was observed, with decreases in both daytime 
and nighttime ambulatory BP.110 A positive effect of oral HT 
on BP was also described in a Canadian study showing that, 
in non-dipper individuals, HT significantly lowers daytime 
BP and induces a smaller nocturnal BP reduction than in dip-
pers. Daytime diastolic BP was significantly and inversely 
related to duration of HT use.111
Studies with transdermal estradiol consistently show 
a reduction of BP during treatment (Table 3). In a study 
performed on 60 hypertensive women, transdermal E2 
after 3 and 6 months significantly decreased systolic and 
diastolic daytime BP.112
By evaluating the different effect of estrogen on daytime 
and nighttime BP, it seems to emerge that, in normotensive 
women, the effect of estrogen is confined mainly to night-
time, with a magnification of the nocturnal BP pressure 
decline.111 In hypertensive women, however, reduction of 
BP induced by estrogen is more evident during the day.112, 113 
Indeed, a prospective study performed on 34 postmenopausal 
women 53 years of age with hypertension found that treat-
ment with a cyclic combination of transdermal estradiol and 
norgestrel for 19 weeks significantly decreases daily systolic 
and diastolic BP.114
HT with progestins  
in hypertensive women
Studies dealing with the effect of progestins in hyper-
tensive postmenopausal women were mainly limited to 
the investigation of DRSP (Table 3). In a randomized 
double-blind  multicentric study performed in hypertensive 
postmenopausal women, the association of 3 mg DRSP 
with 1 mg of oral E2 significantly lowered both office and 
24-hour systolic BP.95 The same authors reported a decrease 
of 6.1 and 4.7 mmHg of daily systolic BP during the  addition 
to E2 of 3 or 2 mg of DRSP, respectively.96 Lately, the same 
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authors evaluated the effects of DRSP on early morning 
BP of mild and slight hypertensive women. The associa-
tion of 3 mg, 2 mg, or 1 mg of DRSP with E2 significantly 
reduced early morning systolic BP. In this study, modifica-
tions induced by E2 alone were not significantly different 
from those observed with placebo. The reduction of early 
morning BP was related to the dose of DRSP, higher doses 
being associated with greater effects both in systolic and 
diastolic BP. The magnitude of these effects is similar to 
that reported for anti-hypertensive medicines. The fact that 
they are confined to the night is probably related to the major 
effect of the renin–angiotensin system at night.97 DRSP (3 
mg), associated with enalapril and administered for two 
weeks in 24 healthy, non-smoking postmenopausal women, 
decreased significantly systolic and diastolic BP in com-
parison to placebo.115 Similarly, a multicentric study on 230 
hypertensive women showed that the association of DRSP 
with angiotensin-converting-enzyme (ACE) inhibitors or 
angiotensin II antagonists induces a significant decrease of 
BP in comparison to placebo.116
Conclusion
The relationship between menopause, hormonal status, age, 
and BP is not clearly defined. Both estrogens and progestins 
may directly influence vasodilation, but their effect may be 
additive or antagonist. In vivo studies also indicate that estro-
gens may activate other mechanisms that regulate BP, such as 
catecholamines or renin–angiotensin–aldosterone systems. 
Some clinical trials which mainly address blood pressure 
modification as a secondary endpoint of the trial have shown 
some negative effects of oral estrogens on office BP. This is 
particularly evident in trials enrolling women several years 
after menopause, and with the use of oral CEE. The data 
are more convincing and reassuring when results obtained 
with 24-hour BP monitoring are considered. These studies 
are much smaller in terms of sample size but more accurate 
and usually performed in recently postmenopausal women. 
These studies do not show major negative effects of oral 
estrogen in the control of BP. Furthermore, they consistently 
show a reduction of BP with the use of transdermal estradiol. 
The effect appears to be evident both in normotensive and 
hypertensive postmenopausal women. Most of the progestins 
tested either do not affect or favor the hypotensive effect of 
estrogens. Among the progestins, DRSP appears to provide 
the best anti-hypertensive effects. 
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